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Accepted 15 March 2018Background: Coronary angiography is performed to assess for obstructive coronary artery disease (CAD), but
“nonobstructive CAD” is a common ﬁnding. Microvascular or vasospastic angina may be relevant, but routine
conﬁrmatory testing is not evidence based and thus rarely performed.
Aim: The aimwas to assess the effect of stratiﬁedmedicine guided by coronary function testing on the diagnosis,
treatment, and well-being of patients with angina and nonobstructive CAD.
Design: The BHF CorMicA trial is a prospective, multicenter, randomized, blinded, sham-controlled trial of
stratiﬁed medicine (NCT03193294). All-comers referred for elective coronary angiography for investigation of
suspected CAD will be screened. Following informed consent, eligible patients with angina and nonobstructive
CAD will be randomized 1:1 immediately in the catheter laboratory to either coronary artery function–guided
diagnosis and treatment (intervention group) or not (control group). Coronary function will be assessed using
a pressure-temperature–sensitive guidewire and adenosine followed by pharmacological testing with
intracoronary acetylcholine. Patients will be stratiﬁed into endotypes with linked therapy. The primary outcome
is change in Seattle Angina Questionnaire score at 6months. Secondary outcomes include safety, feasibility, diag-
nostic utility (impact on diagnosis and diagnostic certainty), and clinical utility (impact on treatment and inves-
tigations). Health status is a key secondary outcome assessed according to the following domains: quality of life,
treatment satisfaction, illness perception, physical activity, and anxiety-depression score. Patients with obstruc-
tive disease who are not randomizedwill form a registry groupwhowill be followed up as a comparator for sec-
ondary outcomes including health status. Health and economic outcomes will be evaluated in the longer term
using electronic health record linkage.
Value: CorMicA is a proof-of-concept clinical trial of a disruptive stratiﬁed intervention with potential beneﬁts to
patients and health care providers.
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Figure 1. Diagnostic coronary angiography lacks sensitivity to detect coronary microvascular dysfunction. The postmortem stereoarteriogram (left), obtained by infusion of a
bismuth microsolution at physiological levels of blood pressure, reveals angiographically smooth coronary arteries with no evidence of CAD. The arteriogram reveals microvessels and
innate collateral connections. Image reproduced with permission: William Fulton, MD Thesis (1963), University of Glasgow. The angiogram (right) of the left coronary tree is normal
with no evidence of CAD. The microvessels are invisible on the standard angiogram. These images highlight that diagnostic coronary angiography lacks sensitivity in detecting
coronary microvascular dysfunction. Clinicians lack information about microvascular and/or vasospastic angina that may lead to suboptimal treatment.
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Stable coronary syndromes: looking beyond epicardial coronary artery disease
Typically, the diagnosis of angina focuses on detecting obstructive
epicardial coronary artery disease (CAD). This allows evidence-based
medical treatment including myocardial revascularization in patients
with obstructive CAD. Recent clinical trials, including ORBITA1 and the
CIAO substudy of ISCHEMIA (NCT02347215), have stimulated pause
for thought about the causes of angina beyond obstructive CAD.
Approximately 4 in 10 patients with angina undergoing elective coro-
nary angiography have nonobstructive CAD.2 Between 2004 and 2008 in
the United States, among almost 400,000 patients undergoing coronary
angiography, 39.2% had no evidence of epicardial CAD.2 In addition, angina
often persists following revascularization procedures.3 The reasons for a
“negative” coronary angiogram are multifactorial, although many of
these patients may have a disorder of coronary artery function including
microvascular or vasospastic angina.4,5 The term stable coronary syndrome
has been proposed to increase physician awareness of these important
diseases.6,7 They may both cause ischemia with nonobstructive coronary
artery disease.8 A recent working group called for research to improve
the diagnosis and management of this common clinical problem.9
The coronary microcirculation includes a trabecular network of
arterioles and microvessels (≤400 μm), which are the ﬁnal pathways for
delivery of blood to the heart.10 Visual assessment of the coronary
angiogram may identify coronary blood vessels of approximately
0.5-mm diameter; however, smaller vessels are not visualized (Figure 1).
The term coronary microvascular dysfunction describes functional
and/or structural changes in the microcirculation that may result in
microvascular angina (MVA). Without objective coronary artery
function testing, the diagnosis and onward treatment for patients with
chest pain and a “negative” angiogram are varied. Importantly, patients
with undiagnosed chest pain (including those who have undergone
cardiac investigations) are at increased risk of cardiovascular events in
the longer term.11Coronary vasomotor, diagnostic tests, and stratiﬁed medicine
Coronary ﬂow reserve (CFR) reﬂects the vasodilator capacity of the
epicardial artery and its microcirculation12 and is prognostically
important.13 CFR may be selectively measured within a coronary artery
using a Doppler or a pressure-temperature–sensitive guidewire with
thermodilution technique. The index of microvascular resistance
(IMR) is a parameter that quantitatively reﬂects microvascular
resistance in a straightforward way using a diagnostic guidewire as an
adjunct to invasive angiography.14 These metrics provide complemen-
tary information on coronary artery andmicrovascular function.15 Phar-
macological testing with intracoronary infusion of acetylcholine (ACh)
and glyceryl trinitrate provides information on endothelial-dependent
and endothelial-independent function, respectively. A pharmacological
protocol involving infusion of incremental concentrations of ACh
provides information on the propensity to vasospasm of the
microvessels or epicardial coronary artery (as revealed by invasive
coronary angiography). Stratiﬁed medicine is the identiﬁcation of key
subgroups of patients (endotypes) within a heterogeneous population,
these endotypes being distinguishable by distinct mechanisms of
disease and/or responses to therapy.16We propose a stratiﬁed approach
to angina involving comprehensive diagnostic tests to deﬁne endotypes
that align with evidence-based therapy.ANOCA: evidence of endotypes linked to treatment strategies
In patients with angina and nonobstructive CAD (ANOCA), the
stratiﬁer is adjunctive use of coronary function tests during coronary
angiography to rule in or rule out microvascular angina, vasospastic
angina, both, or neither (normal coronary function). The study by
Tremmel’s group further conﬁrmed the feasibility of invasive
physiological testing in a reasonably large, selected population. They
noted distinct subgroups of patients with over 75% of the cohort having
an occult explanation for their angina.17
88 T.J. Ford et al. / American Heart Journal 201 (2018) 86–94Microvascular angina is a heterogeneous clinical syndrome, and its
pathogenesis is incompletely understood. In CorMicA, we align this
endotype with the COVADIS working group deﬁnition of MVA.18 This
broad group encompasses various types of coronary microvascular
dysfunction in patients with ANOCA. Our protocol for this endotype
(Table II) is consistent with MVA guidelines from the European Society
of Cardiology based on symptom relief and therapy for underlying
coronary microvascular dysfunction.8 Our protocol is ﬁrst-line
symptomatic relief of MVA with β-blockers. Calcium channel blockers
(CCBs) are recommended where β-blockers are not tolerated or
ineffective. Nicorandil or ranolazine can be added; however, nitrates
are avoided inMVAwithout vasospasmowing to potentially deleterious
effects on exercise tolerance and lack of efﬁcacy.19,20 Where blood
pressure and patient preference permit, statins and angiotensin-
converting enzyme inhibitors (ACEIs)21 are recommended as
potentially disease -modifying agents targeting underlying coronary
microvascular dysfunction.
Vasospastic angina (VSA) is prognostically important and
underdiagnosed despite having effective treatment options.22 In
CorMicA, CCBs are ﬁrst-line therapy with symptomatic and prognostic
beneﬁt.23β-Blockerswhich are used ﬁrst line inMVA should be avoided
because theymay precipitate spasm.24 Although nitrates are avoided for
those with predominant MVA, they often provide symptomatic beneﬁt
for patients with VSA. Smoking cessation and use of statins are
encouraged for pleiotropic beneﬁts on endothelial dysfunction.
Noncardiac chest pain with fully normal coronary artery function
testing is an important diagnosis for both patients and physicians
(Table II). Undiagnosed chest pain is predictive of major adverse cardiac
events,11 whereas quality of life suffers in patients recently diagnosed
with ischemic heart disease.25 Stopping inappropriate antianginal
therapy and secondary preventative medications may provide health
and economic beneﬁts to the patient and health care system.Rationale: standard care of patients with angina and a “negative” coronary
angiogram
Diagnostic tests of coronary vasomotion are rarely used in clinical
practice. Crucially, there is a lack of evidence from randomized,
controlled clinical trials that treatment linked to results of coronary
function tests improves patient well-being and delivers economic
value. Consequently, there are no practice guideline recommendations.
Furthermore, clinicians may lack training and experience in the use of
these tests. The pathophysiology may be uncertain, and without
evidence, the additional time and cost cannot be justiﬁed. This gap
underpins potential suboptimal management and outcomes.
We will address these gaps through a randomized, controlled
clinical trial of stratiﬁed medicine. We will include mechanistic studies
to better understand the pathophysiology of endotypes to develop
novel therapies.Overall objective
The objectives were to assess the effect of stratiﬁedmedicine guided
by coronary function testing on the diagnosis, treatment, and well-
being of patients with ANOCA on invasive coronary angiography. The
stratiﬁcation involves use of complementary tests of coronary function
to diagnose endotypes (subgroups) with protocol linked therapy and
guidance to support clinicians’ ongoing management.
Disorders of coronary artery function, including coronary
microvascular dysfunction and vasospasm, are common in patients
with ANOCA as revealed by coronary angiography.26,27 These disorders
are prognostically important28,29 and associated with high symptom
burden, health care resource utilization, and long-term risk of major
adverse cardiac events.11,28,30,31Hypothesis
Our hypothesis is that routine adjunctive testing of coronary function
will facilitate diagnosis of endotypes and patient stratiﬁcation. This per-
sonalized approach, including pharmacological and nonpharmacological
interventions that are aligned to the patient’s endotype, will lead to im-
provement in angina andwell-being compared to standard carewithout
knowledge of coronary function.
Study design
The British Heart Foundation (BHF) CorMicA trial is a prospective,
double-blind, randomized, sham-controlled clinical trial comparing 2
management approaches to the clinical problem of patients with stable
angina without obstructive coronary disease on invasive angiography.
In the intervention group, a stratiﬁed medicine approach will be
implemented involving diagnosis of endotypes with linked therapy.
The control group involves current optimal management based on
standard coronary angiography (Figure 2).
Setting
The study takes place in 2 large regional hospitals (Golden Jubilee
National Hospital and Hairmyres Hospital) providing invasive care to
all patients in the West of Scotland (population 2.5 million).
Eligibility criteria
Consecutive outpatients undergoing clinically indicated elective
diagnostic angiography for investigation of suspected angina (typical
or atypical angina according to Rose angina questionnaire32) are
screened and invited to participate (Figure 2). Potential participants
have angina medication withheld (except for sublingual nitroglycerin
and aspirin) for 24 hours prior to coronary angiography. Informed
consent is obtained before the coronary angiogram. Exclusion criteria
(Table I) include a noncoronary indication for angiography (eg, valvular
heart disease or hypertrophic cardiomyopathy), signiﬁcant renal
impairment (estimated glomerular ﬁltration rate b30 mL/min) and
obstructive disease on angiography (ie, N50% lesion by diameter steno-
sis in epicardial artery N2.5mm or a fractional ﬂow reserve [FFR] ≤0.80).
A minimum of 400 consecutive patients undergoing elective invasive
coronary angiography patients is expected to be screened to enroll
150 subjects within 24 months. Consenting patients who are not
randomized, for example, because of the presence of obstructive disease
or for logistical reasons, will enter into a registry involving similar
follow-up to the randomized trial participants, including completion
of health status questionnaires and follow-up N3 years using electronic
case record linkage.
Randomization, implementation, and blinding
Participants are enrolled by research staff on the ward before the
angiogram is performed. The standard care management strategy is
established and recorded before randomization. The treatment plan is
based on all of the clinical information including the results of the
angiogram. FFR may be measured in intermediate lesions of uncertain
functional signiﬁcance. If the eligibility criteria are fulﬁlled, the patient
will then be randomized in the catheter laboratory to the intervention
group (coronary function tests disclosed) or standard care group with
invasive angiography only (coronary function tests measured but not
disclosed) using a Web-based randomization system provided by the
Robertson Centre for Biostatistics (University of Glasgow). The random-
ization sequence involves block lengths randomized in blocks of length
4, that is, every 20 allocations consists of 4 blocks, 2 of length 4 and 2 of
length 6, in a random order. The allocation sequence is on a 1:1 basis
between the intervention group and the control group. The sequence
Figure 2. Schematic study design: ﬂow diagram.
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soon as the allocation is assigned on the Web-based portal.
Blinding and adherence
Angiography-guided group and blinding
In patients randomized to the angiography-guided group, coronary
function tests are measured in the same way as in the intervention
group except that the results will not be disclosed. The research staff
obscure the hemodynamic monitor from the clinicians, nurses, and
patients such that it is impossible for them to observe the guidewire
information either in the catheter laboratory or afterward. Electronic
displays on other hemodynamic monitors that may have been visible
in the catheter laboratory are disabled. Complete blinding is ensured
with the use of a second cardiologist (Dr Tom Ford) to superviseintracoronary ACh while monitoring the angiogram for visual display
of coronary diameter and electrocardiogram during which time the
attending clinician is blinded. Quality control checks, including
assessments of equalized pressure recordings and veriﬁcation of
symptoms and hemodynamic changes with intravenous adenosine,
are conducted in the usual way. Pharmacological tests are performed
in an identical fashion in both groups. Adherence to monitoring is
prospectively recorded by the research staff.
Diagnostic strategy groups
Disclosed: coronary artery function testing group
Invasive coronary artery function aremeasured anddisclosed after the
coronary angiogram, permitting the cardiologist to identify endotypes,
reclassify the initial diagnosis based on coronary angiography, and
Table I
Eligibility criteria
Inclusion criteria
Aged ≥18 y
A clinically indicated plan for invasive coronary angiography
Symptoms of angina (according to the Rose and Seattle angina questionnaires).
Exclusion criteria
A noncoronary indication for invasive angiography, eg, valve disease, hypertrophic
obstructive cardiomyopathy
During the angiogram: obstructive disease evident in a main coronary artery (diameter
N2.5 mm), ie, a coronary stenosis N50% or an FFR ≤0.80.⁎
Substudies: contraindication to contrast-enhanced CMR, eg, severe renal dysfunction
(glomerular ﬁltration rate b30 mL/min), non–CMR-compatible pacemaker or
deﬁbrillator.
CMR, cardiovascular magnetic resonance.
⁎ Patients with obstructive disease are eligible to participate in the registry follow-up.
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formed by practice guidelines (Table II and Supplementary File 1).8
Blinded: usual care group
Invasive coronary artery function is measured but not disclosed;
management is based on standard coronary angiography alone.
Protocol: coronary physiology measurements
CFR, IMR, and FFR are measured using previously described
methods.14,33 In brief, intravenous heparin (50-70 U/kg) will be admin-
istered, and a guiding catheter without side holes is used to interrogate
the coronary artery. A pressure-temperature sensor guidewire
(PressureWire X, Abbott Vascular, Santa Clara, CA) wirelessly transmits
data to a personal computer with dedicated analysis software
(Coroventis, Uppsala, Sweden). The wire sensor tip is positioned at the
tip of the guiding catheter, and the pressure measurement from the
wire is equalizedwith that of the guiding catheter. The sensor is then po-
sitioned in the distal third of the coronary artery followed by 3
intracoronary injections of saline (3 mL) at room temperature. The
mean transit time is measured with each bolus and averaged to calculate
the restingmean transit time. An intravenous infusion of adenosine (140
μg·kg−1·min−1) will be administered via a large peripheral or central
vein to induce steady-state maximal hyperemia, and 3 more injections
of 3 mL of room temperature saline will then be performed. The transit
time is automatically measured after each set of injections and averaged
to calculate the hyperemic mean transit time. Simultaneous measure-
ments ofmean aortic pressure (by guiding catheter) andmean distal cor-
onary pressure (by pressure wire) are also made during maximal
hyperemia. IMR is calculated as the distal coronary pressure at maximal
hyperemia multiplied by the hyperemic mean transit time.14 Increased
IMR (≥25) is representative of microvascular dysfunction.17 CFR is calcu-
latedusing thermodilution as restingmean transit timedividedbyhyper-
emic mean transit time34 (abnormal CFR is deﬁned as ≤2).35 FFR is
calculated by the ratio of mean distal coronary pressure to mean aortic
pressure at maximal hyperemia; abnormal FFR is deﬁned as ≤0.80.33
Coronary vasoreactivity testing
The target coronary artery is the left anterior descending coronary
artery. If technical factors, for example vessel tortuosity, preclude as-
sessment of this artery, then the left circumﬂex or right coronary artery
will be selected. Assessment of endothelium-dependent coronary vaso-
motor function will be performed by intracoronary infusion of ACh via
the guiding catheter at concentrations of 0.182, 1.82, and 18.2 μg/mL
(10−6, 10−5, and 10−4 mol/L, respectively) infused at 1 mL/min for 2
minutes via a mechanical pump.36 An assessment of symptoms and a
12-lead electrocardiogram are performed before starting the infusion
and then again after each infusion period. The coronary angiogram isalso performed at each time point in an identical projection that delin-
eates the artery without foreshortening. A ﬁnal test of the propensity
to coronary vasospasm will be performed using 100 μg of ACh (5.5 mL
of 10−4 mol/L over 20 seconds). This is reduced to 50 μg of ACh if the
right coronary artery is interrogated. Epicardial artery spasm may be
focal or diffuse. Focal constriction is deﬁned as a circumscribed transient
vessel narrowing within the borders of 1 isolated or 2 neighboring cor-
onary segments. Diffuse constriction is diagnosed when the vessel
narrowing is observed in ≥2 adjacent coronary segments.37 Finally, cor-
onary angiography is repeated following an intracoronary bolus of 300
μg (3 mL) of nitroglycerin (Abbott Laboratories, Santa Clara, CA), an
endothelium-independent vasodilator.
Quantitative coronary angiography
Quantitative coronary analysis of the target artery, for example, left
anterior descending, will be performed using computer-assisted angio-
graphic analysis (QAngio XA7.3, Medis, Leiden, Netherlands) by trained
cardiologists at the Golden Jubilee National Hospital Core Laboratory
who are blinded to the clinical and physiological results. The coronary
artery (typically left anterior descending artery)measurements are per-
formed in the region where the greatest change had occurred during
coronary reactivity testing.38 End-diastolic cine frames that best show
the segment are selected, and calibration of the video and cine images
is accomplished with the diameter of the guide.
The deﬁnitions of coronary artery function disorders are shown in
Table II. Patients with obstructive disease are eligible to participate in
the registry follow-up. Coronary artery diameter change (% from base-
line) will be measured in response to both ACh and glyceryl trinitrate.
Severe endothelial dysfunction is deﬁned by ≥20% luminal constriction
during ACh infusion (up to 10−4M); this ﬁnding implies signiﬁcant re-
duction in coronary artery blood ﬂow with prognostic implications
when compared with patients whose arteries are b20% constricted.39
Outcomes
Primary outcome
Health status and symptomswill be assessed at baseline and again at
6 months using the Seattle Angina Questionnaire (SAQ).40 The primary
end point is the mean difference in the within-subject change in SAQ
between the groups at 6months from baseline. A team of health profes-
sionals blinded to group allocation will send and collate the question-
naires from study participants. The SAQ is the most widely used and
validated patient-reported outcome measure for angina. Although de-
rived from a mostly male cohort with obstructive CAD, validation stud-
ies in women have been completed showing prognostic value.41-43 In
theWISE and iPOWER cohorts, SAQ severity correlatedwith physiologic
metrics of coronarymicrovascular dysfunction.44,45 It has been used ex-
tensively in other studies of ANOCA.25,46,47 Furthermore, in the land-
mark COURAGE study, the SAQ proved a valid metric of functional
angina and quality of life in patients despite apparently successful PCI.48
Secondary outcomes
The key prespeciﬁed secondary outcomes are described in Table III.
The independent clinician responsible for the patients’ care adjudicates
on the ﬁnal diagnosis which is prospectively completed on a predis-
charge questionnaire (Supplementary File 2). Where patients have
both MVA and a positive ACh test result for epicardial vasospasm, the
treating physician will document the main diagnosis based on their in-
terpretation of results in the context of the clinical presentation. Reclas-
siﬁcation of diagnosis after disclosure of detailed coronary artery
function results will be assessed. Participant contacts will continue for
up to 3 years, and then longer-term follow-up for medication use and
health outcomes will continue using electronic record linkage. A key
Table II
Deﬁnitions of coronary artery function disorders with linked therapy
Endotype Disorder of coronary artery function Linked pharmacotherapy
Microvascular
angina
(nonobstructive
CAD and proven
CMD)
↑Microvascular
resistance
IMR ≥25. IMR is a quantitative method for speciﬁcally assessing microvascular
function independent resting hemodynamics. IMR = distal coronary pressure *
transit time (average time for 3 saline bolus runs at hyperemia).
Baseline therapy: Consider aspirin, statin and ACEI
therapy in all patients. PRN sublingual GTN
Antianginal Rx
1st Line: β-blocker (eg, carvedilol 6.25 mg BD
uptitrated)
2nd Line: CCBs substituted (non-DHP, eg,
verapamil 40 mg BD uptitrated) where β-blockers
are not tolerated or ineffective.
3rd line: add in therapy
• CCB: DHP (eg, amlodipine)—only for those on
β-blockers
• Nicorandil (5 mg BD, uptitrated)
• Ranolazine (375 mg BD, uptitrated)
↓ Coronary
vasorelaxation
CFR by thermodilution b2.0. This reﬂects the inability to increase coronary ﬂow
above 2 times the resting ﬂow.
↓
Microvasodilator
capacity
Resistive reserve ratio b2.0. This reﬂects the vasodilator capacity of the
microcirculation to change from baseline to hyperemia (resistance at rest divided
by resistance at hyperemia).
Microvascular
spasm
Angina during ACh infusion or bolus with typical ischemic ST-segment changes and
epicardial coronary constriction b90% reduction in epicardial coronary artery
diameter. Represents inappropriate susceptibility microvascular constriction.
Vasospastic
angina
Epicardial spasm Epicardial coronary artery spasm is deﬁned as a reduction in coronary diameter
N90% following intracoronary ACh in comparison with baseline resting condition
following intracoronary GTN administration in any epicardial coronary artery
segment together with symptoms and ST segment deviation on the
electrocardiogram.
Baseline therapy: If atherosclerosis or endothelial
impairment, aspirin and statin should be
considered. PRN sublingual GTN
Antianginal Rx
1st line: CCB, eg, verapamil 40 mg BD uptitrated
2nd line: add nitrate, eg, isosorbide mononitrate
10 mg BD
3rd line: change nitrate to nicorandil, eg,
nicorandil 5 mg BD
Mixed MVA/VSA CMD and
epicardial
vasospasm
Epicardial spasm plus any abnormality of
•Microvascular resistance
•Coronary vasorelaxation
•Microvasodilator capacity
Baseline therapy: Consider aspirin, statin, and
ACEI therapy in all patients. PRN sublingual GTN
Antianginal Rx
1st line: CCB, eg, verapamil 40 mg BD uptitrated
2nd line: add nicorandil 5mg BD
Obstructive CAD N50% lesion by diameter stenosis in epicardial artery N2.5 mm or an FFR ≤0.8030 Baseline therapy: If atherosclerosis or endothelial
impairment, patients should be considered for
aspirin, statin, and ACEI therapy
Consideration of revascularization, antianginal
therapy as per ESC guidelines.
Noncardiac Nil Exclusion of diffuse or obstructive epicardial coronary disease (FFR N0.8) without
any of the following abnormalities of coronary function: CFR b2.0, IMR ≥25, or
functional angina/spasm during ACh.
Cessation of antianginal therapy. stop antiplatelet
and statin unless other indication
Consider noncardiac investigation or referral
where appropriate (eg, psychology,
gastroenterology)
ACh, Acetylecholine; CMD, coronary microvascular dysfunciton; VSA, vasospastic angina; GTN, glyceryl trinitrate; ESC, European Society of Cardiology.
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registry who are followed up for health status and adverse events.
Feasibility
The study has been peer-reviewed by the British Heart Foundation,
and the protocol has been approved by the West of Scotland Research
Ethics Service (Reference 16/WS/0192). The trial will be conducted in
line with Guidelines for Good Clinical Practice in Clinical Trials.
Statistical considerations
The CorMicA trial has a comprehensive statistical analysis plan that
governs all statistical aspects of the study authored by the trial statisti-
cian before any unblinded data are seen. The analysis plan is based on
intention-to-treat principles in linewith CONSORT guidelines. It focuses
on estimation of treatment effect differences with 95% CIs and P values.
All prespeciﬁed secondary outcome analyses will be reported in study
publications to further inform efﬁcacy, safety, and cost-effectiveness.
Continuous outcomes will be analyzed using linear regression with
adjustment for baseline levels where these are available. Where contin-
uous data are clearly not normally distributed (eg, laboratory variables),
standard transformations will be applied to achieve approximate nor-
mality prior to analysis. Appropriate alternative regression methods
will be applied to other types of data (eg, logistic regression for binary
outcomes). The angiographic parameters will be correlatedwith clinical
outcomes. Clinical data will be made available to the data coordinating
center (the Robertson Centre for Biostatistics) through an electronic
clinical report form.Sample size calculation
To detect a mean group difference of change in SAQ score of 9
units, we calculated that a sample size of 70 patients per group
gave 80% power to detect a between-group difference in SAQ score
between the groups. This calculation assumed the 5% signiﬁcance
level (2-sample t test of the mean group difference of within-
subject ΔSAQ). This projected effect is consistent with other studies,
for example, the observed difference in the change in SAQ frequency
score with ranolazine (9.4; P= .027) versus placebo in patients with
a reduced CFR.45Follow-up and timetable
Quality of life and health status questionnaires (Table III) will be
completed at 6, 12, and 24 months (or study close out, whichever
comes sooner). Follow-up assessments for adverse events will be per-
formed by the clinical research staff by telephone or in person (eg, out-
patient clinic review), as appropriate. Medical records will also be
checked. Follow-up contact will occur at 6-month intervals until the
last patient has achieved a minimum of 6-month follow-up. Follow-up
in the longer term (ie, ≥3 years) will be supported by electronic record
linkage with central government health records. The active phase of
the project will be completed within 30 months. Follow-up procedures
will be the same for patients in both of the groups.Writtenmanagement
guidance for each endotype, informed by practice guidelines,8 will be
provided to the cardiologists, general practitioners, and nurse practi-
tioners with advice to start, stop, and optimize treatment (including
Table III
Secondary outcomes
Secondary outcomes Time frame
Feasibility and safety Feasibility of the stratiﬁed medicine approach deﬁned by protocol
compliance as measured by deviations from the protocol.
Up to 3 y
Enrolment rates, procedure duration, and protocol compliance
relating to enrolment, crossover, integrity of blinding, adherence
with therapy during follow-up, and compliance
with follow-up assessments.
Procedure-related serious adverse events Day 1
Diagnostic utility Diagnosis of endotypes (disease strata): obstructive CAD, coronary
vasospastic angina, microvascular angina, endothelial dysfunction
(no angina), normal (noncardiac, normal
coronary function results, no angina).
Day 1
Impact of disclosure of the coronary function test results on the
diagnosis and certainty of the diagnosis (diagnostic utility)
Clinical utility Impact of disclosure of the coronary function test results on
medical decisions (including treatment and investigations)
and to compare these decisions against medical decisions
formed by an independent panel of experts (reference data set).
Day 1
Assess the relationships between cardiovascular risk factors,
reﬂected by validated risk scores (eg, ASSIGN, JBS3), and parameters
of coronary function in medically managed patients.
Vascular function To assess whether patients have abnormal peripheral vascular function
(using in vitro wire myography studies of vascular function).
42 d
Cardiac stress perfusion MRI Assess the diagnostic accuracy of stress perfusion magnetic resonance
(CMR) imaging for identiﬁcation of endotypes
based on reference tests of coronary function.
42 d
Detection of clinically signiﬁcant (actionable) incidental ﬁndings
using magnetic resonance imaging. The incidental
ﬁndings may be cardiac or noncardiac.
Detection of myocardial pathology using multiparametric CMR
Health status Health status and symptoms will be
assessed at baseline and again at 6 m,
12 m, and closeout using the SAQ. The secondary outcome is the
within-subject change in SAQ score over time.
6, 12, and 24 m and/or closeout up to 3 y
Assess the participants' general health status and self-reported
quality of life using the EQ5D questionnaire.
Assess the participants' self-reported levels of anxiety and
depression using the Patient Health Questionnaire-4
Assess the participants' self-reported levels of treatment satisfaction
using the Treatment Satisfaction Questionnaire for Medication
Assess the participants' perception of their illness using
the brief Illness Perception Questionnaire
Assess the participants' self-reported activity during daily life
(Duke Activity Status Index) and physical activity
(International Physical Activity Questionnaire)
Obstructive disease registry Health status and symptoms will be assessed using the
SAQ and health status questionnaires for patients with
obstructive disease entered into the registry. A comparison
of mean within-subject change in the health status domains
above will be made between the registry patients
and the randomized study groups.
6 m
Health economics Assess resource utilization including primary and secondary
care costs for tests, procedures and outpatient visits,
and medicines between the randomized groups
Up to 36 m
ASSIGN, ASSIGN score estimates a person's risk of developing cardiovascular disease developed for use in Scotland; JBS3, Joint British Societies recommendations on the prevention of Car-
diovascular Disease (JBS3) is a calculator for cardiovascular disease risk.
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(Supplementary File 1).
Ancillary studies
Laboratory analyses will focus on mechanistic pathways causally
implicated in abnormalities of coronary artery function and myocardial
perfusion. These will include endothelial cytokines, markers of
inﬂammation (eg, high-sensitivity C-reactive protein), metabolic status
(plasma glucose, lipids), and biomarkers of cardiovascular dysfunction
(eg, N-terminal pro b-type natriuretic peptide (NT-proBNP)). These
will be obtained at baseline and repeated at 12months. Multiparametric
stress perfusion cardiacmagnetic resonance imaging at 1.5 T (Magnetom
Avanto, Siemens Healthcare) will be obtained within 42 days of enrol-
ment. Incidental ﬁndings will be disclosed, but the stress perfusionresultswill be blinded. All patientswill be offered theopportunity to par-
ticipate in a substudy of peripheral vascular biology undertaken using
wire myography of peripheral resistance vessels isolated from gluteal
subcutaneous fat biopsies.
Trial management and governance
Standard operating procedures will be used, and adverse events will
be adjudicated by clinicians independent of the research group and
blind to the study data. Progress in the trial will be monitored by the
Trial Manager (Katriona Brooksbank, PhD) and Sponsor representatives
from Pharmacy and ResearchManagement. The studywill be subject to
internal and external audit that is routinely coordinated by the Sponsor.
Based on the safety experience in a recent diagnostic study17 in which
no serious adverse events were reported, a Data and Safety Monitoring
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An annual report will be submitted to the Ethics Committee on a
12-month basis. The ﬂow diagram illustrates conservative estimates of
patient enrolment and activity on a single site. The study will follow
STARD (http://www.equator-network.org/reporting-guidelines/stard/)
and CONSORT (http://www.consort-statement.org/) guidelines. Adverse
events are deﬁned and reviewed as outlined in Supplementary File 3.
Ethics
The BHF CorMicA trial has full UK National Research Ethics Service
approval (Reference 16/WS/0192).
Registration
The ClinicalTrials.gov registration is NCT03193294.
Sources of funding
CorMicA is an investigator-initiated clinical trial that is funded by the
British Heart Foundation (PG/17/2532884; RE/13/5/30177). No
companies are involved in this study.
The trial sponsor is the Golden Jubilee Research Foundation. The
authors are solely responsible for the design and conduct of the study,
all analyses, the drafting and editing of the paper, and its ﬁnal contents.
Discussion
Diagnostic tests of coronary function are rarely performed for
patients with ANOCA in daily practice. To date, these tests have mainly
been used for research purposes. On the other hand, the tests may be
considered as “reference” measures for the diagnosis of disorders of
coronary function. There are several reasons why coronary function
tests are not used by clinicians.
First, to our knowledge, there has never been a randomized trial of a
diagnostic strategy involving routine tests of coronary function linked to
medical decisions. Hence, there are no data to conﬁrm that use of the
tests in appropriate patients might lead to beneﬁts. Accordingly, the
recommendations in practice guidelines (eg, Class IIb) are based on
the weakest forms of evidence (Level of Evidence C).37 We believe
that this lack of evidence reﬂects the lack of relevant trials and paucity
of clinical evidence such that the management of individual patients
in daily practice is heterogeneous and empirical. Second, there are
some disincentives to the use of these tests, including amodest increase
in the duration of the invasive diagnostic procedure and the associated
costs. Third, although Ach testing has been shown to be safe and used
widely for research purposes,26 Ach is not licensed for parenteral use
and is not available in daily practice in some health care systems (eg,
in the UK National Health Service). Finally, some clinicians may take
the view that even if microvascular or vasospastic angina were
diagnosed objectively, no speciﬁc treatments are available and therapy
would be much the same. We suggest that patients and health care
providers may take a different view. Clariﬁcation of a diagnosis to rule
in or rule out a problemwill help clinicians tomake informed treatment
decisions.49 Patients with conﬁrmed microvascular or vasospastic
angina are content with a precise diagnosis allowing medications to
be uptitrated as appropriate. Patients with completely normal invasive
assessment of coronary artery function can have antianginal therapy
appropriately stopped, and alternative (eg, noncardiac) causes of chest
pain can be investigated.
Chest pain is amajor cause of planned andunplanned attendances at
hospital with potentially avoidable admissions.11 Clariﬁcation of the
diagnosis and treatment may improve patient satisfaction and well-
being and help clinicians to appropriately target therapy.50 There are
potential cost-savings if the enhanced clariﬁcation of symptomstranslates to future reductions in unnecessary tests, treatments, and
hospital attendances for chest pain.
Coronary microvascular dysfunction is associated with poor
prognosis.11,28,30,31,34 Lee et al recently reported data on invasive met-
rics of coronary artery function in 313 patients with NOCAD (median
658 days). They showed that the group with physiologically important
coronary microvascular dysfunction (low CFR and a high IMR) was at
the greatest risk of major adverse cardiac events (HR 4.91 [1.54-15.7];
P = .007) even compared to multivessel CAD (HR 3.64 [1.24-10.7];
P = .019) and diabetes mellitus (HR 2.71 [1.05-7.02]; P = .039).51
The patients with microvascular angina may beneﬁt from targeted
therapy with evidence-based treatments for angina (eg,
β-blockers, angiotensin-converting enzyme inhibitors, and statins).
Recent position papers call for pathophysiological insights into
disease-driving processes that are integrated into a new taxonomy
allowing personalized disease management.52 The BHF CorMicA
trial is the ﬁrst to assess a routine approach using stratiﬁed medi-
cine in patients with angina but nonobstructive coronary disease.
This diagnostic intervention is disruptive to current standards of
care. Should our hypotheses be conﬁrmed, this developmental clin-
ical trial will inform the design and rationale for undertaking a larg-
er multicenter trial.
Acknowledgments
We thank the staff and patients whowill support this study, and the
BHF for ﬁnancial support.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ahj.2018.03.010.
References
1. Al-Lamee R, Thompson D, Dehbi HM, et al. Percutaneous coronary intervention in
stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet
2018;391(110115):31-40.
2. Patel MR, Peterson ED, Dai D, et al. Low diagnostic yield of elective coronary
angiography. N Engl J Med 2010;362:886-95.
3. Abbate A, Biondi-Zoccai GG, Agostoni P, et al. Recurrent angina after coronary
revascularization: a clinical challenge. Eur Heart J 2007;28:1057-65.
4. Camici PG, d'Amati G, Rimoldi O. Coronary microvascular dysfunction: mechanisms
and functional assessment. Nat Rev Cardiol 2015;12:48-62.
5. Ong P, Athanasiadis A, Borgulya G, et al. High prevalence of a pathological response
to acetylcholine testing in patients with stable angina pectoris and unobstructed cor-
onary arteries. The ACOVA Study (Abnormal COronary VAsomotion in patients with
stable angina and unobstructed coronary arteries). J Am Coll Cardiol 2012;59:655-62.
6. Berry C. Stable coronary syndromes: the case for consolidating the nomenclature of
stable ischemic heart disease. Circulation 2017;136(5):437-9.
7. Ford TJ, Corcoran D, Berry C. Stable coronary syndromes: pathophysiology, diagnostic
advances and therapeutic need. Heart 2018;104:284-92.
8. Task Force M, Montalescot G, Sechtem U, et al. 2013 ESC guidelines on the
management of stable coronary artery disease: the Task Force on the management
of stable coronary artery disease of the European Society of Cardiology. Eur Heart J
2013;34:2949-3003.
9. Bairey Merz CN, Pepine CJ, Walsh MN, et al. Ischemia and no obstructive coronary
artery disease (INOCA): developing evidence-based therapies and research agenda
for the next decade. Circulation 2017;135:1075-92.
10. Chilian WM. Coronary microcirculation in health and disease. Summary of an NHLBI
workshop. 1997;95:522-8.
11. Jordan KP, Timmis A, Croft P, et al. Prognosis of undiagnosed chest pain: linked
electronic health record cohort study. BMJ 2017;357:j1194.
12. Gould KL, Lipscomb K, Hamilton GW. Physiologic basis for assessing critical coronary
stenosis. Instantaneous ﬂow response and regional distribution during coronary
hyperemia as measures of coronary ﬂow reserve. Am J Cardiol 1974;33:87-94.
13. Gulati M, Cooper-DeHoff RM, McClure C, et al. Adverse cardiovascular outcomes in
women with nonobstructive coronary artery disease: a report from the Women's
Ischemia Syndrome Evaluation Study and the St James Women Take Heart Project.
Arch Intern Med 2009;169:843-50.
14. Fearon WF, Balsam LB, Farouque HM, et al. Novel index for invasively assessing the
coronary microcirculation. Circulation 2003;107:3129-32.
15. Ford TJ, Corcoran D, Berry C. Coronary artery disease: physiology and prognosis. Eur
Heart J 2017;38:1990-2.
16. Hingorani AD, Windt DA, Riley RD, et al. Prognosis research strategy (PROGRESS) 4:
stratiﬁed medicine research. BMJ 2013;346, e5793.
94 T.J. Ford et al. / American Heart Journal 201 (2018) 86–9417. Lee BK, Lim HS, Fearon WF, et al. Invasive evaluation of patients with angina in the
absence of obstructive coronary artery disease. Circulation 2015;131:1054-60.
18. Ong P, Camici PG, Beltrame JF, et al. International standardization of diagnostic
criteria for microvascular angina. Int J Cardiol 2018;250:16-20.
19. Redﬁeld MM, Anstrom KJ, Levine JA, et al. Isosorbide mononitrate in heart failure
with preserved ejection fraction. N Engl J Med 2015;373:2314-24.
20. Russo G, Di Franco A, Lamendola P, et al. Lack of effect of nitrates on exercise stress test
results in patients with microvascular angina. Cardiovasc Drugs Ther 2013;27:229-34.
21. Kaski JC, Rosano G, Gavrielides S, et al. Effects of angiotensin-converting enzyme
inhibition on exercise-induced angina and ST segment depression in patients with
microvascular angina. J Am Coll Cardiol 1994;23:652-7.
22. Sato K, Kaikita K, Nakayama N, et al. Coronary vasomotor response to intracoronary
acetylcholine injection, clinical features, and long-term prognosis in 873 consecutive
patients with coronary spasm: analysis of a single-center study over 20 years. J Am
Heart Assoc 2013;2, e000227.
23. Nishigaki K, Inoue Y, Yamanouchi Y, et al. Prognostic effects of calcium channel
blockers in patients with vasospastic angina. Circ J 2010;74:1943-50.
24. Robertson RM,Wood AJ, VaughnWK, et al. Exacerbation of vasotonic angina pectoris
by propranolol. Circulation 1982;65:281-5.
25. Williams MC, Hunter A, Shah A, et al. Symptoms and quality of life in patients with
suspected angina undergoing CT coronary angiography: a randomised controlled
trial. Heart 2017;103:995-1001.
26. Ong P, Athanasiadis A, Borgulya G, et al. Clinical usefulness, angiographic characteris-
tics, and safety evaluation of intracoronary acetylcholine provocation testing among
921 consecutive white patients with unobstructed coronary arteries. Circulation
2014;129:1723-30.
27. Sara JD, Widmer RJ, Matsuzawa Y, et al. Prevalence of coronary microvascular
dysfunction among patients with chest pain and nonobstructive coronary artery
disease. JACC Cardiovasc Interv 2015;8:1445-53.
28. Johnson BD, Shaw LJ, Pepine CJ, et al. Persistent chest pain predicts cardiovascular
events in women without obstructive coronary artery disease: results from the
NIH-NHLBI-sponsored Women's Ischaemia Syndrome Evaluation (WISE) study. Eur
Heart J 2006;27:1408-15.
29. Murthy VL, Naya M, Foster CR, et al. Improved cardiac risk assessment with
noninvasive measures of coronary ﬂow reserve. Circulation 2011;124:2215-24.
30. Maddox TM, Stanislawski MA, Grunwald GK, et al. Nonobstructive coronary artery
disease and risk of myocardial infarction. JAMA 2014;312:1754-63.
31. Jespersen L, Hvelplund A, Abildstrom SZ, et al. Stable angina pectoris with no
obstructive coronary artery disease is associated with increased risks of major
adverse cardiovascular events. Eur Heart J 2012;33:734-44.
32. Cook DG, Shaper AG, Macfarlane PW. Using theWHO (Rose) angina questionnaire in
cardiovascular epidemiology. Int J Epidemiol 1989;18:607-13.
33. De Bruyne B, Baudhuin T, Melin JA, et al. Coronary ﬂow reserve calculated from
pressure measurements in humans. Validation with positron emission tomography.
Circulation 1994;89:1013-22.
34. Pijls NHJ. Coronary thermodilution to assess ﬂow reserve: validation in humans.
Circulation 2002;105:2482-6.
35. Murthy VL, Naya M, Taqueti VR, et al. Effects of sex on coronary microvascular
dysfunction and cardiac outcomes. Circulation 2014;129:2518-27.36. Lerman A, Holmes DR, Bell MR, et al. Endothelin in coronary endothelial dysfunction
and early atherosclerosis in humans. Circulation 1995;92:2426-31.
37. Beltrame JF, Crea F, Kaski JC, et al. International standardization of diagnostic criteria
for vasospastic angina. Eur Heart J 2017;38(33):2565-8.
38. Reriani M, Raichlin E, Prasad A, et al. Long-term administration of endothelin
receptor antagonist improves coronary endothelial function in patients with early
atherosclerosis. Circulation 2010;122:958-66.
39. Suwaidi JA, Hamasaki S, Higano ST, et al. Long-term follow-up of patients with
mild coronary artery disease and endothelial dysfunction. Circulation
2000;101:948-54.
40. Spertus JA, Winder JA, Dewhurst TA, et al. Development and evaluation of the Seattle
angina questionnaire: a new functional status measure for coronary artery disease.
J Am Coll Cardiol 1995;25:333-41.
41. Berecki-Gisolf J, Humphreyes-Reid L, Wilson A, et al. Angina symptoms are associated
with mortality in older women with ischemic heart disease. Circulation 2009;120:
2330-6.
42. Kimble LP, Dunbar SB, Weintraub WS, et al. The Seattle angina questionnaire:
reliability and validity in women with chronic stable angina. Heart Dis 2002;4:
206-11.
43. Patel K, Qintar M, Arnold S, et al. Reliability and responsiveness of Seattle angina
questionnaire in women with coronary artery disease. J Am Coll Cardiol
2017;69.
44. Mygind ND, Michelsen MM, Pena A, et al. Coronary microvascular function
and cardiovascular risk factors in women with angina pectoris and no obstruc-
tive coronary artery disease: the iPOWER study. J Am Heart Assoc 2016;5,
e003064.
45. Bairey Merz CN, Handberg EM, Shufelt CL, et al. A randomized, placebo-controlled
trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction
(CMD): impact on angina and myocardial perfusion reserve. Eur Heart J 2016;37:
1504-13.
46. Jespersen L, Abildstrom SZ, Hvelplund A, et al. Persistent angina: highly prevalent and
associated with long-term anxiety, depression, low physical functioning, and quality
of life in stable angina pectoris. Clin Res Cardiol 2013;102:571-81.
47. Villano A, Di Franco A, Nerla R, et al. Effects of ivabradine and ranolazine in patients
with microvascular angina pectoris. Am J Cardiol 2013;112:8-13.
48. WeintraubWS, Spertus JA, Kolm P, et al. Effect of PCI on quality of life in patients with
stable coronary disease. N Engl J Med 2008;359:677-87.
49. Herrmann J, Kaski JC, Lerman A. Coronary microvascular dysfunction in the clinical
setting: from mystery to reality. Eur Heart J 2012;33:2771-2782b.
50. Cannon III RO, Epstein SE. "Microvascular angina" as a cause of chest pain with
angiographically normal coronary arteries. Am J Cardiol 1988;61:1338-43.
51. Lee JM, Jung JH, Hwang D, et al. Coronary ﬂow reserve and microcirculatory
resistance in patients with intermediate coronary stenosis. J Am Coll Cardiol
2016;67:1158-69.
52. Kirchhof P, Sipido KR, Cowie MR, et al. The continuum of personalized cardiovascular
medicine: a position paper of the European Society of Cardiology. Eur Heart J
2014;35:3250-7.
